Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Election of Directors
Director Nominees |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
|
5,432,232 |
301,172 |
94.75% |
5.25% |
|
5,455,219 |
278,185 |
95.15% |
4.85% |
|
5,427,266 |
306,138 |
94.66% |
5.34% |
|
5,463,225 |
270,179 |
95.29% |
4.71% |
|
5,490,982 |
242,422 |
95.77% |
4.23% |
Reappointment of External Auditors
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
|
6,388,758 |
49,767 |
99.23% |
0.77% |
Approval of the Continuation of Crescita’s Shareholder Rights Plan
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
AGAINST |
FOR |
AGAINST |
|
Shareholder Rights Plan approved |
5,481,368 |
252,036 |
95.60% |
4.40% |
About
Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and a commercial stage prescription product. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For more information visit, www.crescitatherapeutics.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20250605776909/en/
FOR MORE INFORMATION, PLEASE CONTACT:
Vice-President, Reporting and Corporate Affairs
Email:lkisa@crescitatx.com
Source: